- Home
- SILO
SILO
Silo Pharma Inc.
as 12-18-2024 9:58am EST
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 4.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 596.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $4.50 | Next Earning Date: | 11-12-2024 |
| Revenue: | $72,102 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1.86% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Silo Pharma Inc. (SILO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weisblum Eric | SILO | CEO and President | Nov 20 '24 | Buy | $0.93 | 5,000 | $4,625.00 | 182,932 |
Latest Silo Pharma Inc. News
SILO Breaking Stock News: Dive into SILO Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
GlobeNewswire
a month ago
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
Simply Wall St.
a month ago
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)
GlobeNewswire
2 months ago
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
GlobeNewswire
3 months ago
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
GlobeNewswire
4 months ago
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
GlobeNewswire
4 months ago
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
GlobeNewswire
5 months ago
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
Compare SILO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SILO Silo Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.